Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers

Cancer Research

Volumn 74, Issue 4, 2014, Pages 1141-1152

  Karst, Alison M ^a   Jones, Paul M ^a   Vena, Natalie ^a   Ligon, Azra H ^a   Liu, Joyce F ^a   Hirsch, Michelle S ^a   Etemadmoghadam, Dariush ^b,c   Bowtell, David D L ^b,c   Drapkin, Ronny ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN E; CYSTADENOCARCINOMA, SEROUS; EPITHELIAL CELLS; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 84894267929     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2247     Document Type: Article

References (49)

1. Peter Boyle, Bernard Levin, editors. World cancer report 2008. Geneva: International Agency for Research on Cancer; 2008.
2. Nik NN, Vang R, Shih IM, Kurman RJ. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol 2013;16:27-45.
3. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35.
4. Dubeau L, Drapkin R. Coming into focus: the nonovarian origins of ovarian cancer. Ann Oncol 2013;24 Suppl 8:viii28-viii35.
5. TCGA. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
6. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmo-ghadam D, Cowin P, et al. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS ONE 2010; 5:e11408
7. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010;10:803-8.
8. Siu KT, Rosner MR, Minella AC. An integrated view of cyclin E function and regulation. Cell Cycle 2012;11:57-64.
9. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300.
10. Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol 2002;12:1817-27.
11. Loeb KR, Kostner H, Firpo E, Norwood T, D Tsuchiya K, Clurman BE, et al. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 2005;8:35-47.
12. Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, et al. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS ONE 2012;7:e30996.
13. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary che-moresistance in ovarian carcinomas. Clin Cancer Res 2009;15: 1417-27.
14. Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M, Gorringe KL, et al. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS ONE 2010;5:e15498.
15. Liu JF, Hirsch MS, Lee H, Matulonis UA. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol 2009;115:401-6.
16. Mehrad M, Ning G, Chen EY, Mehra KK, Crum CP. Apathologist'sroad map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol 2010;17:293-302.
17. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008;27:1-9.
18. Karst AM, Drapkin R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat Protoc 2012;7:1755-64.
19. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 2011; 108:7547-52.
20. Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lans-dorp PM, et al. Dissociation among in vitro telomerase activity, telo-mere maintenance, and cellular immortalization. Proc Natl Acad Sci USA 1998;95:14723-8.
21. Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia 2008;10:450-61.
22. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2: 401-4.
23. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
24. Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010;116: 2621-34.
25. Ofir M, Hacohen D, Ginsberg D. MiR-15 and miR-16 are direct tran-scriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res 2011;9:440-7.
26. Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 1997;17:453-9.
27. Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci USA 2007;104: 4089-94.
28. Smith AP, Henze M, Lee JA, Osborn KG, Keck JM, Tedesco D, et al. Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland. Oncogene 2006;25: 7245-59.
29. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-6.
30. Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, Peters KL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001;80:176-80.
31. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31:161-9.
32. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria isapreferred site for early adenocarcinomainwomen with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30: 230-6.
33. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006;444: 633-7.
34. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9:701-13.
35. Brown NR, Noble ME, Lawrie AM, Morris MC, Tunnah P, Divita G, et al. Effects of phosphorylation of threonine 160 on cyclin-depen-dent kinase 2 structure and activity. J Biol Chem 1999;274: 8746-56.
36. Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 2011;145:435-46.
37. Jones RM, Mortusewicz O, Afzal I, Lorvellec M, Garcia P, Helleday T, et al. Increased replication initiation and conflicts with transcription underlie cyclin E-induced replication stress. Oncogene 2013;32: 3744-53.
38. Podhorecka M, Skladanowski A, Bozko P. H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids 2010;pii: 920161.
39. Olive PL, Banath JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 2006;1:23-9.
40. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010;2010:932371.
41. Sehdev AS, Kurman RJ, Kuhn E, Shih Ie M. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol 2010;23:844-55.
42. Minella AC, Grim JE, Welcker M, Clurman BE. p53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability. Onco-gene 2007;26:6948-53.
43. Nowee ME, Snijders AM, Rockx DA, de Wit RM, Kosma VM, Hama-lainen K, et al. DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. J Pathol 2007;213: 46-55.
44. Snijders AM, Nowee ME, Fridlyand J, Piek JM, Dorsman JC, Jain AN, et al. Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene 2003; 22:4281-6.
45. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 2010;70:5074-84.
46. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, et al. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet 2012;8:e1002538.
47. Sheu JJ, Choi JH, Guan B, Tsai FJ, Hua CH, Lai MT, et al. Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol 2013;229:559-68.
48. Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 2012;22:106-16.
49. Chaudhury I, Sareen A, Raghunandan M, Sobeck A. FANCD2 regulates BLM complex functions independently of FANCI to promote replication fork recovery. Nucleic Acids Res 2013;41: 6444-59.